Transcatheter aortic valve replacement (TAVR) is increasingly being used in younger patients, though long-term outcomes and valve durability remain uncertain.
The expansion of transcatheter aortic valve replacement to younger patients highlights the critical need for careful patient selection, shared decision-making, and lifetime management strategies due to limited long-term durability data.
Absolute Event Rate: 0% vs 0%
Transcatheter aortic valve replacement has rapidly expanded from high-risk populations to younger patients with aortic stenosis. This shift raises important questions about valve durability, reintervention strategies, and long-term outcomes compared with surgical aortic valve replacement. Younger patients often present with unique anatomical challenges, including bicuspid aortic valves, and are expected to outlive their first valve prosthesis, making lifetime management a central concern. While new valve technologies show promise, long-term data remain limited. Careful patient selection, shared decision-making, and ongoing prospective studies are essential to guide the role of TAVR in this population.
Gilhooley et al. (Fri,) reported a other. Transcatheter aortic valve replacement (TAVR) is increasingly being used in younger patients, though long-term outcomes and valve durability remain uncertain.